AccurEdit Therapeutics

Founded in 2021, AccurEdit is dedicated to developing and commercializing safe, effective, and target-specific in vivo gene editing therapies, along with delivery technologies, for the treatment of severe or life-threatening genetic and acquired diseases worldwide. AccurEdit is advancing multiple pipeline products. ART001 (ATTR) and ART002 (PCSK9), its first two leading assets, have entered into human clinical trials and both demonstrate the potential to be the Best-in-Class or First-in-class therapies in respective fields. AccurEdit has established an industry-leading end-to-end technology platform for in vivo gene editing therapies. AccurEdit is the first company in China to advance its LNP-based in vivo gene editing product into human studies and the only company in the world to obtain IND clearances for in vivo gene editing product in both China and the United States.